Cyclin E and survival in patients with breast cancer

New England Journal of Medicine

Volumn 347, Issue 20, 2002, Pages 1566-1575

  Keyomarsi, Khandan ^a,b   Tucker, Susan L ^b   Buchholz, Thomas A ^b   Callister, Matthew ^b   Ding, Ye ^c   Hortobagyi, Gabriel N ^b   Bedrosian, Isabelle ^b   Knickerbocker, Christopher ^c   Toyofuku, Wendy ^c   Lowe, Michael ^c   Herliczek, Thaddeus W ^c   Bacus, Sarah S ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c WADSWORTH CENTER   (United States)

^d Quantitative Diagnostics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN D3; CYCLIN E;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; RISK ASSESSMENT; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CYCLIN D1; CYCLIN E; CYCLINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0037079027     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021153     Document Type: Article

References (34)

1. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large European randomized trials. J Clin Oncol 2001;19;1688-97. (Erratum, J Clin Oncol 2001;19:2583.]
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352:930-42.
3. Idem. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-67.
4. Dou Q-P, Pardee AB, Keyomarsi K. Cyclin E - A better prognostic marker for breast cancer than cyclin D? Nat Med 1996;2:254.
5. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci U S A 1996;93:15215-20.
6. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993;90:1112-6.
7. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994;54:380-5.
8. Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995;11:941-50.
9. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991;66:1197-206.
10. Dou Q-P, Levin AH, Zhao S, Pardee AB. Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res 1993;53:1493-7.
11. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995;15:2612-24.
12. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
13. Buckley MF, Sweeney KJE, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
14. Sgambato A, Doki Y, Schieren I, Weinstein IB. Effects of cyclin E overexpression on cell growth and response to transforming growth factor β depend on cell context and p27Kip1 expression. Cell Growth Differ 1997;8:393-405.
15. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. In: Meijer L, Guidet S, Philippe M, eds. Progress in Cell Cycle Research. Vol. 3. New York: Plenum Press, 1997:171-91.
16. Porter D, Zhang N, Danes C, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive low-molecular-weight forms. Mol Cell Biol 2001;21:6254-69.
17. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: Pathologic correlations and prognostic implications. Hum Pathol 2001;32:89-94.
18. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
19. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E over-expression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996;74:874-80.
20. Wang A, Yoshimi N, Suzui M, Yamauchi A, Tarao M, Mori H. Different expression patterns of cyclins A, D1 and E in human colorectal cancer. J Cancer Res Clin Oncol 1996;122:122-6.
21. Scuderi R, Palucka KA, Pokrovskaja K, Bjorkholm M, Wiman KG, Pisa P. Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood 1996;87:3360-7. [Erratum, Blood 1996;88:4083.]
22. Bacus SS, Flowers JL, Press MF, Bacus JW, McCarty KS Jr. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol 1988;90:233-9.
23. Bacus SS, Goldschmidt R, Chin D, Moran G, Weinberg D, Bacus JW. Biological grading of breast cancer using antibodies to proliferating cells and other markers. Am J Pathol 1989;135:783-92.
24. Bacus SS, Ruby SG. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma. Pathol Annu 1993;28:179-204.
25. Taylor SR, Titus-Ernstoff L, Stitely S. Central values and variation of measured nuclear DNA content in imprints of normal tissues determined by image analysis. Cytometry 1989;10:382-7.
26. Berchuck A, Boente MP, Kerns BJ, et al. Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol 1992;44:61-5.
27. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000;60:481-9.
28. Lees E, Faha B, Dulic V, Reed SI, Harlow E. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev 1992;6:1874-85.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
30. Greenwood M. The natural duration of cancer. Rep Public Health Med Subjects 1926;33:1-26.
31. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
32. Spruck CH, Won K-A, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
33. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997;17:453-9.
34. Yamashita JI, Ogawa M, Ikei S, et al. Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: Possible role ofpolymorphonuclear leucocyte elastase in the progression of human breast cancer. Br J Cancer 1994;69:72-6.